CTT Pharmaceutical Holdings, Inc. provided an update on the successful commercial introduction of its sublingual strips with Aurora Cannabis and intentions for product portfolio expansion. On October 6, 2019, Aurora Cannabis Inc. commenced sales of its Dissolve Strips, developed in collaboration with CTT, to the Canadian medical market. The Dissolve Strips are a novel sublingual cannabinoid delivery technology that neither requires combustion nor inhalation, and has been proven to deliver rapid cannabinoid uptake and increased bioavailability; The first production run has now completely sold out, and the products have received strong positive feedback from patients.

The Company anticipates that Aurora will recommence supply of the Dissolve Strips to the medical market early in the new year, with production runs supporting consistent product availability for the medical market; Based on the successful market introduction, CTT and Aurora are in the process of developing additional SKUs, including CBD infused strips and THC:CBD balanced strips for the medical and consumer markets; Launch of Dissolve Strips for the consumer markets is anticipated for March 2020.